NDA 021282 · Reckitt Benckiser
Mucinex
Guaifenesin · Oral · Expectorant
Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Jul 12, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
147
31 Phase 3, 6 recruiting
FAERS reports
29,629
14,639 serious, 2,164 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 29, 2026.
Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- MUCINEX · GUAIFENESIN 600MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter
- MUCINEX · GUAIFENESIN 1.2GM · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Guaifenesin" as an intervention, any sponsor and status, largest first.
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract InfectionsPivotal-lookingCompleted
Reckitt Benckiser LLCIndustry
NCT01537081 · 2,810 participants · Start Sep 2011 · Primary completion Mar 2012
Drug: Mucinex; Immediate-release Guaifenesin and 1 more · For: Acute Upper Respiratory Tract Infection
Sites: Hoover, Alabama; Bell Gardens, California; Harbor City, California · 43 sites in all
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationPivotal-lookingCompleted
Hospital do Rim e HipertensãoAcademic, hospital or other
NCT03468478 · 1,209 participants · Start Jun 18, 2017 · Primary completion Mar 18, 2021
Drug: Sirolimus; Everolimus and 1 more · For: Kidney Transplant Infection
Sites: São Paulo, Brazil
- Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTIPivotal-lookingCompleted
Reckitt Benckiser Inc.Industry
NCT01202279 · 1,179 participants · Start Oct 2009 · Primary completion Apr 2010
Drug: Guaifenesin · For: Acute Upper Respiratory Track Infection
Sites: Mesa, Arizona; Carmichael, California; Fresno, California · 24 sites in all
- Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori InfectionPivotal-lookingCompleted
Phathom Pharmaceuticals, Inc.Industry
NCT04167670 · 1,046 participants · Start Dec 10, 2019 · Primary completion Mar 10, 2021
Drug: Vonoprazan; Amoxicillin and 2 more · For: Helicobacter Pylori Infection
Sites: Anniston, Alabama; Athens, Alabama; Birmingham, Alabama · 153 sites in all
- Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After HepatectomyPivotal-lookingStatus unknown
Shuqun ChengAcademic, hospital or other
NCT02399033 · 1,000 participants (planned) · Start Jun 2014 · Primary completion Jul 2019
Drug: Xihuang Capsules · For: Hepatocellular Carcinoma
Sites: Shanghai, China
- Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple TherapiesPivotal-lookingCompleted
Kaohsiung Veterans General Hospital.Academic, hospital or other
NCT03779074 · 918 participants · Start Sep 3, 2018 · Primary completion Dec 31, 2021
Drug: 10d bismuth quadruple therapy; 14d hybrid therapy and 1 more · For: Helicobacter Pylori Infection
Sites: Kaohsiung City, Taiwan
- Fixed Dose MMF vs Concentration Controlled MMF After Renal TransplantationPivotal-lookingCompleted
Erasmus Medical CenterAcademic, hospital or other
NCT00166244 · 901 participants · Start May 2003 · Primary completion Mar 2005
Drug: Mycophenolate Mofetil · For: De Novo Renal Transplant Recipient.
Sites: New Lambton, Australia; Brisbane, Australia; Clayton, Australia · 67 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,481
- dyspnoea2,219
- fatigue1,810
- nausea1,771
- diarrhoea1,677
- pneumonia1,671
- cough1,601
- headache1,535
- dizziness1,415
- pain1,260
- off label use993
- vomiting953
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 164 |
| 2005 | 231 |
| 2006 | 291 |
| 2007 | 277 |
| 2008 | 336 |
| 2009 | 400 |
| 2010 | 683 |
| 2011 | 681 |
| 2012 | 826 |
| 2013 | 765 |
| 2014 | 912 |
| 2015 | 2,136 |
| 2016 | 3,169 |
| 2017 | 2,376 |
| 2018 | 2,134 |
| 2019 | 2,119 |
| 2020 | 2,281 |
| 2021 | 1,420 |
| 2022 | 1,700 |
| 2023 | 1,801 |
| 2024 | 1,863 |
| 2025 | 2,159 |
| 2026 | 902 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Over-the-counter (OTC) medications for acute cough in children and adults in community settings.
Smith SM, Schroeder K, Fahey T · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Ephedrine- and guaifenesin-induced nephrolithiasis.
Bennett S, Hoffman N, Monga M · J Altern Complement Med 2004 · Systematic Review
- The effect of oral guaifenesin on pediatric chronic rhinitis: A pilot study.
Dodson KM, Indeyeva YA, Ma J, et al. · Am J Otolaryngol 2023 · Randomized Controlled Trial
- Guaifenesin as a treatment for primary dysmenorrhea.
Marsden JS, Strickland CD, Clements TL · J Am Board Fam Pract 2004 · Clinical Trial, Randomized Controlled Trial
- Efficacy of phenylephrine-phenylpropanolamine in the treatment of rhinitis.
Erffmeyer JE, McKenna WR, Lieberman PL, et al. · South Med J 1982 · Clinical Trial, Comparative Study
- The role of guaifenesin in the treatment of sinonasal disease in patients infected with the human immunodeficiency virus (HIV).
Wawrose SF, Tami TA, Amoils CP · Laryngoscope 1992 · Clinical Trial, Randomized Controlled Trial
Sponsor: Reckitt Benckiser
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.